President Donald Trump’s nominee for FDA Commissioner, Martin A. Makary, MD, sought to assure senators that if confirmed, he would support efforts to expedite reviews of new drugs indicted for rare diseases, as well as tailor to individual diseases the agency’s regulatory review-to-approval pathways designed to advance drugs to treat …
Read More »